Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:45:25 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Z:NNVC - NANOVIRICIDES INC - http://www.nanoviricides.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NNVC - Z0.20.8601·1.020.20.88+0.03093.6249.91953480.891  0.93  0.882.2299  0.8519:47:41Feb 0215 min RT 2¢

Recent Trades - Last 10 of 348
Time ETExPriceChangeVolume
19:47:41Z0.92590.075920
19:36:11Z0.940.093
19:30:29Z0.93990.0899210
19:04:44Z0.9310.08149
19:04:35Z0.930.08900
17:28:31Z0.92590.07591,028
16:24:10Z0.90720.057210
16:15:19Z0.92580.07581,091
16:11:53Z0.92590.075910
16:10:53Z0.91730.0673100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-02 08:30U:NNVCNews ReleaseNanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres
2026-01-13 08:30U:NNVCNews ReleaseNanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2
2025-12-01 08:30U:NNVCNews ReleaseNanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles
2025-11-17 08:30U:NNVCNews ReleaseNanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position
2025-11-14 08:30U:NNVCNews ReleaseNanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2
2025-11-12 17:01U:NNVCNews ReleaseNanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
2025-11-11 08:30U:NNVCNews ReleaseNanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
2025-11-10 08:30U:NNVCNews ReleaseNanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo
2025-11-05 08:30U:NNVCNews ReleaseNanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT
2025-11-03 08:30U:NNVCNews ReleaseNanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd
2025-10-29 08:45U:NNVCNews ReleaseTreating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive
2025-10-27 08:45U:NNVCNews ReleaseNanoViricides to Present at the PODD 2025 Conference in Boston on October 27
2025-10-22 08:45U:NNVCNews ReleaseIn Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides
2025-10-20 08:45U:NNVCNews ReleaseA Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus
2025-10-15 08:45U:NNVCNews ReleaseNanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses
2025-09-30 08:45U:NNVCNews ReleaseNanoViricides, Inc. Has Filed its Annual Report
2025-09-11 08:30U:NNVCNews ReleaseRETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
2025-09-09 08:51U:NNVCNews ReleaseNanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
2025-08-18 08:30U:NNVCNews ReleaseA Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials
2025-07-30 08:30U:NNVCNews ReleaseMeasles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides